Friday, March 24, 2017 2:42:10 PM
GW Pharma produces a single molecule compound formula. We're setting up to do precision expression of the entourage effect. We're setting up to offer personalized medicine based on the entourage effect, not single molecule compounds. It's like comparing apples to oranges Alan. My advice is do some research on the "entourage affect".
If you're not using precision cultivation methods like we've developed, you simply can not control with precision the chemical expression. It's what we learned and developed in our relationship with MIT.
If you actually made an effort to understand what we're doing on the science side, you might learn that we're on the cutting edge of cannabis research and development for pharmaceuticals.
It is our ability to "augment" the production of cannabis as stated by the DEA, which is looking for such a producer, that is driving our efforts.
The cannabis industry in the U.S. is under a cloud of uncertainty. Our technology costs 5X's more in CAPEX, but we offer 80% reduction in cost of goods and 50% increase in production. Simply put, cannabis growers and investors haven't embraced our methods because it requires an infrastructure investment industry players are afraid to make.
So we're simply going to keep it to ourselves and become a producer since the DEA opened the door for us to do so last August. All of this is explained in our public Deck.
Recent INQD News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/01/2023 07:35:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2023 01:00:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 02:46:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 12:10:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2023 10:02:30 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM